keyword
MENU ▼
Read by QxMD icon Read
search

Oligometastatic

keyword
https://www.readbyqxmd.com/read/29331524/strategies-and-technical-challenges-for-imaging-oligometastatic-disease-recommendations-from-the-european-organisation-for-research-and-treatment-of-cancer-imaging-group
#1
REVIEW
Nandita M deSouza, Yan Liu, Arturo Chiti, Daniela Oprea-Lager, Géraldine Gebhart, Bernard E Van Beers, Ken Herrmann, Frederic E Lecouvet
Patients with oligometastatic disease (OMD) often have controllable symptoms, and cures are possible. Technical improvements in surgery and radiotherapy have introduced the option of metastasis-directed ablative therapies as an adjunct or alternative to standard-of-care systemic therapies. Several clinical trials and registries are investigating the benefit of these therapeutic approaches across several cancer sites. This requires that patients are correctly included and followed with appropriate imaging. This article discusses the evidence and offers recommendations for the implementation of standard-of-care (Response Evaluation Criteria in Solid Tumours measurements on computed tomography [CT], magnetic resonance imaging [MRI] and bone scintigraphy) and advanced imaging modalities (functional, metabolic and radionuclide targeted) for identifying and following up patients with OMD...
January 10, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29329933/combined-hepatic-and-pulmonary-metastasectomies-from-colorectal-carcinoma-data-from-the-prospective-spanish-registry-2008-2010
#2
Jose R Jarabo, Ana M Gómez, Joaquín Calatayud, Carlos A Fraile, Elena Fernández, Nuria Pajuelo, Raul Embún, Laureano Molins, Juan J Rivas, Florentino Hernando
INTRODUCTION: Resection of both liver and lung metastases from colorectal carcinoma (CRC) is a standard of care in selected patients with oligometastatic disease. We present here the analysis of the subgroup of patients undergoing combined surgery from the Spanish Group of Surgery of Pulmonary Metastases (PM) from Colorectal Carcinoma (GECMP-CCR-SEPAR). METHODS: We analyze characteristics, survival and prognostic factors of patients undergoing combined resection from March-2008 to February-2010 and followed-up during at least 3 years, from the prospective multicenter Spanish Registry...
January 9, 2018: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/29324212/managing-patients-with-oligometastatic-non-small-cell-lung-cancer
#3
Sarah Jo Stephens, Michael J Moravan, Joseph K Salama
Metastatic lung cancer has long been considered incurable, with the goal of treatment being palliation. However, a clinically meaningful number of these patients with limited metastases (approximately 25%) are living long term after definitive treatment to all sites of active disease. These patients with so-called oligometastatic disease likely represent a distinct clinical group who may possess a more indolent biology compared with their more widely metastatic counterparts. Hellman and Weichselbaum proposed the existence of the oligometastatic state, on the basis of the spectrum theory of cancer spread...
January 2018: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29324207/oligometastatic-non-small-cell-lung-cancer-how-should-we-define-and-manage-it
#4
David E Gerber
No abstract text is available yet for this article.
January 2018: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29320333/prostate-specific-membrane-antigen-pet-clinical-utility-in-prostate-cancer-normal-patterns-pearls-and-pitfalls
#5
Michael S Hofman, Rodney J Hicks, Tobias Maurer, Matthias Eiber
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with extraordinary tumor-to-background contrast. Currently, gallium 68 (68Ga)-PSMA-11 (or HBED-PSMA) is the most widely used radiotracer for PSMA positron emission tomography (PET)/computed tomography (CT) or PSMA PET/magnetic resonance (MR) imaging...
January 2018: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29318366/-surgical-innovations-in-treatment-of-metastatic-colorectal-cancer-complexity-of-metastatic-surgery-as-example-for-personalized-medicine
#6
REVIEW
C Hackl, S M Brunner, K M Schmidt, H J Schlitt
BACKGROUND: Extensive, bilobular and multifocal colorectal liver metastases (CLM) or metastases that are critically situated require an experienced surgeon and advanced surgical techniques to enable curative resection. OBJECTIVE: This article describes the toolbox of hepato-oncologic surgery including functional augmentation of liver segments by portal vein embolization/ligation, combinations of ablation and resection, two-stage resections and in situ split liver resection, also known as associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)...
January 9, 2018: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/29315174/oligorecurrent-nodal-prostate-cancer-long-term-results-of-an-elective-nodal-irradiation-approach
#7
Sebastien Tran, Sandra Jorcano, Teresa Falco, Giorgio Lamanna, Raymond Miralbell, Thomas Zilli
OBJECTIVES: The objective of this study was to report long-term results of elective nodal radiotherapy (ENRT) in prostate cancer (PCa) patients with oligorecurrent nodal disease after primary treatment. METHODS: Data of 53 oligorecurrent PCa patients (N1 and/or M1a) with ≤5 nodal metastases (n=108) treated with ENRT combined with androgen deprivation therapy (ADT) between 2004 and 2016 were retrospectively reviewed. Median prostate-specific antigen (PSA) and PSA doubling time (DT) were 3...
January 8, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29310420/the-role-of-stereotactic-body-radiation-therapy-in-oligometastatic-colorectal-cancer-clinical-case-report-of-a-long-responder-patient-treated-with-regorafenib-beyond-progression
#8
Michela Roberto, Rosa Falcone, Federica Mazzuca, Livia Archibugi, Nadia Castaldi, Andrea Botticelli, Mattia Falchetto Osti, Paolo Marchetti
RATIONALE: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%. PATIENT CONCERNS: A 55-year-old man affected by mCRC, treated with regorafenib combined with stereotactic body radiotherapy (SBRT), showing a durable response. INTERVENTIONS: After 6 months of regorafenib, a PET/CT scan revealed a focal uptake in a solid lung nodule which was treated with SBRT, whereas continuing regorafenib administration...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29286005/current-concepts-and-trends-in-the-treatment-of-bone-metastases-in-patients-with-advanced-prostate-cancer
#9
REVIEW
Miriam Hegemann, Moritz Maas, Steffen Rausch, Simon Walz, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer
Bone metastases have a major impact on quality of life and survival of patients with advanced prostate cancer. In the last decade, the development and approval of substances inhibiting the vicious cycle of bone metastases have enabled the reduction of complications caused by bone metastases in patients with castration-resistant prostate cancer. These drugs have raised awareness of the importance of skeletal-related events which in the meantime represent an important end point also in trials using agents not specifically designed for bone lesions...
December 29, 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/29280465/prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-for-prostate-cancer-distribution-of-disease-and-implications-for-radiation-therapy-planning
#10
Sandeep K Gupta, Tahne Watson, Jim Denham, Thomas P Shakespeare, Natalie Rutherford, Nicholas McLeod, Kevin Picton, Paul Ainsworth, Tony Bonaventura, Jarad M Martin
PURPOSE: To explore the prostate-specific membrane antigen (PSMA)-avid distribution of prostate cancer (PC) on positron emission tomography (PET), both at the time of initial diagnosis and at the time of relapse after definitive local treatment. METHODS AND MATERIALS: A total of 179 PSMA PET scans in patients with nil or ≤3 lesions on conventional imaging were retrospectively categorized into 3 subgroups: group A, high-risk PC with no prior definitive therapy (n=34); group B, prior prostatectomy (n=75); and group C, prior radiation therapy (n=70)...
November 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29277446/phase-i-trial-of-stereotactic-mr-guided-online-adaptive-radiation-therapy-smart-for-the-treatment-of-oligometastatic-or-unresectable-primary-malignancies-of-the-abdomen
#11
Lauren Henke, Rojano Kashani, Clifford Robinson, Austen Curcuru, Todd DeWees, Jeffrey Bradley, Olga Green, Jeff Michalski, Sasa Mutic, Parag Parikh, Jeffrey Olsen
PURPOSE/OBJECTIVES: SBRT is used to treat oligometastatic or unresectable primary abdominal malignancies, although ablative dose delivery is limited by proximity of organs-at-risk (OAR). Stereotactic, magnetic resonance (MR)-guided online-adaptive radiotherapy (SMART) may improve SBRT's therapeutic ratio. This prospective Phase I trial assessed feasibility and potential advantages of SMART to treat abdominal malignancies. MATERIALS/METHODS: Twenty patients with oligometastatic or unresectable primary liver (n = 10) and non-liver (n = 10) abdominal malignancies underwent SMART...
December 22, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29240541/surveillance-or-metastasis-directed-therapy-for-oligometastatic-prostate-cancer-recurrence-a-prospective-randomized-multicenter-phase-ii-trial
#12
Piet Ost, Dries Reynders, Karel Decaestecker, Valérie Fonteyne, Nicolaas Lumen, Aurélie De Bruycker, Bieke Lambert, Louke Delrue, Renée Bultijnck, Tom Claeys, Els Goetghebeur, Geert Villeirs, Kathia De Man, Filip Ameye, Ignace Billiet, Steven Joniau, Friedl Vanhaverbeke, Gert De Meerleer
Purpose Retrospective studies suggest that metastasis-directed therapy (MDT) for oligorecurrent prostate cancer (PCa) improves progression-free survival. We aimed to assess the benefit of MDT in a randomized phase II trial. Patients and Methods In this multicenter, randomized, phase II study, patients with asymptomatic PCa were eligible if they had had a biochemical recurrence after primary PCa treatment with curative intent, three or fewer extracranial metastatic lesions on choline positron emission tomography-computed tomography, and serum testosterone levels > 50 ng/mL...
December 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29225693/cytoreductive-prostate-radiotherapy-in-oligometastatic-prostate-cancer-a-single-centre-analysis-of-toxicity-and-clinical-outcome
#13
Giulia Riva, Giulia Marvaso, Matteo Augugliaro, Dario Zerini, Cristiana Fodor, Gennaro Musi, Ottavio De Cobelli, Roberto Orecchia, Barbara Alicja Jereczek-Fossa
Objectives: The current standard of care for patients with metastatic prostate cancer (mPCa) at diagnosis is androgen deprivation therapy (ADT) with or without anti-androgen and chemotherapy. The aim of this study was to define the role of a local radiotherapy (RT) treatment in the mPCa setting. Methods: We retrospectively reviewed data of patients with PCa and bone oligometastases at diagnosis treated in our institution with ADT followed by cytoreductive prostate-RT with or without RT on metastases...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/29224900/single-fraction-stereotactic-ablative-body-radiotherapy-for-oligometastasis-outcomes-from-132-consecutive-patients
#14
S Gandhidasan, D Ball, T Kron, M Bressel, M Shaw, J Chu, S Chander, G Wheeler, N Plumridge, B Chesson, S David, S Siva
AIMS: Stereotactic ablative body radiotherapy (SABR) is currently used to treat oligometastases, but the optimum dose/fractionation schedule is unknown. In this study, we evaluated outcomes after single fraction SABR in patients with oligometastatic disease. MATERIALS AND METHODS: Single institutional retrospective review of patients treated with single fraction SABR for one to three oligometastases between 2010 and 2015. The primary outcome was freedom from widespread disease defined as distant recurrence not amenable to surgery or SABR; or recurrence with four or more metastases...
December 7, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29199719/retrospective-study-of-efficacy-and-safety-of-neoadjuvant-docetaxel-carboplatin-and-trastuzumab-in-her2-positive-locally-advanced-and-oligometastatic-breast-cancer-an-indian-experience
#15
A Tiwari, A Gogia, Svs Deo, N K Shukla, S Mathur, D N Sharma
BACKGROUND: The neoadjuvant chemotherapy in HER2-positive breast cancer consists of a chemotherapy backbone and HER2-directed therapy. The increase in cardiotoxicity by the use of trastuzumab with an anthracycline-based regimen has led to the use of nonanthracycline-based alternative regimens. The docetaxel, carboplatin, and trastuzumab (TCH) are one such regimen. The efficacy and toxicity of this regimen have not been widely studied in Indian patients. AIMS: This retrospective study aims to evaluate the efficacy and toxicity of neoadjuvant TCH regimen in locally advanced and oligometastatic HER2-positive breast cancer in Indian patients...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29196095/prognostic-value-of-combining-a-quantitative-image-feature-from-positron-emission-tomography-with-clinical-factors-in-oligometastatic-non-small-cell-lung-cancer
#16
Garrett L Jensen, Christine M Yost, Dennis S Mackin, David V Fried, Shouhao Zhou, Laurence E Court, Daniel R Gomez
BACKGROUND AND PURPOSE: Oligometastatic non-small cell lung cancer (NSCLC) is a heterogeneous condition with few known risk stratification factors. A quantitative imaging feature (QIF) on positron emission tomography (PET), gray-level co-occurrence matrix energy, has been linked with outcome of nonmetastatic NSCLC. We hypothesized that GLCM energy would enhance the ability of models comprising standard clinical prognostic factors (CPFs) to stratify oligometastatic patients based on overall survival (OS)...
November 28, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29191586/outcome-of-radical-local-treatment-of-non-small-cell-lung-cancer-patients-with-synchronous-oligometastases
#17
Margriet Kwint, Iris Walraven, Sjaak Burgers, Koen Hartemink, Houke Klomp, Joost Knegjens, Marcel Verheij, José Belderbos
OBJECTIVES: Patients with stage IV non-small cell lung cancer (NSCLC) are considered incurable and are mainly treated with palliative intent. This patient group has a poor overall survival (OS) and progression free survival (PFS). The purpose of this study was to investigate PFS and OS of NSCLC patients diagnosed with synchronous oligometastatic disease who underwent radical treatment of both intrathoracic disease and metastases. MATERIALS AND METHODS: Patients with NSCLC and oligometastatic disease at diagnosis, who were treated with radical intent between 2008 and 2016, were included in this observational study...
October 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29191358/-stereotactic-body-radiation-therapy-for-oligometastatic-prostate-cancer
#18
REVIEW
Jean-Emmanuel Bibault
INTRODUCTION: The first line treatment of metastatic prostate cancer is medical or surgical androgen-deprivation. This treatment however has significant side effects that can affect the patients' quality of life. For oligometastatic patients, a new therapeutic approach, focusing on local treatment of metastases, is emerging. METHODS: A systematic review of studies published on Stereotactic Body Radiation Therapy (SBRT) for oligometastatic prostate cancer was performed using results from search request on MEDLINE...
November 27, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29188197/68ga-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-in-advanced-prostate-cancer-current-state-and-future-trends
#19
REVIEW
Cristian Udovicich, Marlon Perera, Michael S Hofman, Shankar Siva, Andres Del Rio, Declan G Murphy, Nathan Lawrentschuk
The early and accurate detection of prostate cancer is important to ensure timely management and appropriate individualized treatment. Currently, conventional imaging has limitations particularly in the early detection of metastases and at prostate-specific antigen (PSA) levels < 2.0 ng/mL. Furthermore, disease management such as salvage radiotherapy is best at low PSA levels. Thus, it is critical to capture the disease in the oligometastatic stage as disease progression and commencement of systemic therapies can be delayed by metastasis-directed therapy...
December 2017: Prostate International
https://www.readbyqxmd.com/read/29185632/-local-treatment-in-oligometastatic-urological-malignancies-evidence-of-wishful-thinking
#20
Massimo Valerio, Yannick Cerantola, Ilaria Lucca, Dominik Berthold, Patrice Jichlinski
In the past, it was generally considered that the window of curability had been missed in metastatic solid cancers. At present, novel evidence suggests that oligometastatic cancer might be amenable to a multimodal curative treatment, including ablation of the primary tumour. In this article, we summarise the indications, the controversies and future perspectives of local treatment in oligometastatic urological malignancies.
November 29, 2017: Revue Médicale Suisse
keyword
keyword
65559
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"